small molecule

RHAPSIDO

REMIBRUTINIB

Loss of exclusivityJanuary 2043latest FDA-listed patent expiry

CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand name	RHAPSIDO
Active ingredient	REMIBRUTINIB
Strength	25MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	September 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12419889	January 2043	use U-4281
10457647	November 2034	use U-4280
9512084	November 2034	substance, product

Regulatory exclusivity

Code	Expires
NCE	September 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Novartis